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Abstract
Background: Lung cancer is still the main cause of cancer death worldwide despite the availability of targeted
therapies and immune-checkpoint inhibitors combined with chemotherapy. Cancer cell heterogeneity and primary
or acquired resistance mechanisms cause the elusive behaviour of this cancer and new biomarkers and active drugs
are urgently needed to overcome these limitations. p65BTK, a novel isoform of the Bruton Tyrosine Kinase may
represent a new actionable target in non-small cell lung cancer (NSCLC).
Methods: p65BTK expression was evaluated by immunohistochemistry in 382 NSCLC patients with complete clinico-
pathological records including smoking habit, ALK and EGFR status, and in metastatic lymph nodes of 30 NSCLC
patients. NSCLC cell lines mutated for p53 and/or a component of the RAS/MAPK pathway and primary lung cancer-
derived cells from Kras/Trp53 null mice were used as a preclinical model. The effects of p65BTK inhibition by BTK
Tyrosine Kinase Inhibitors (TKIs) (Ibrutinib, AVL-292, RN486) and first-generation EGFR-TKIs (Gefitinib, Erlotinib) on cell
viability were evaluated by MTT. The effects of BTK-TKIs on cell growth and clonogenicity were assessed by crystal
violet and colony assays, respectively. Cell toxicity assays were performed to study the effect of the combination of
non-toxic concentrations of BTK-TKIs with EGFR-TKIs and standard-of-care (SOC) chemotherapy (Cisplatin, Gemcitabine,
Pemetrexed).
Results: p65BTK was significantly over-expressed in EGFR-wild type (wt) adenocarcinomas (AdC) from non-smoker
patients and its expression was also preserved at the metastatic site. p65BTK was also over-expressed in cell lines
mutated for KRAS or for a component of the RAS/MAPK pathway and in tumors from Kras/Trp53 null mice. BTK-TKIs
were more effective than EGFR-TKIs in decreasing cancer cell viability and significantly impaired cell proliferation and
clonogenicity. Moreover, non-toxic doses of BTK-TKIs re-sensitized drug-resistant NSCLC cell lines to both target- and
SOC therapy, independently from EGFR/KRAS status.
(Continued on next page)
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: marialuisa.lavitrano@unimib.it; emanuela.grassilli@unimib.it
†Federica Giordano and Valentina Vaira contributed equally to this work and
should be considered co-first authors.
†Marialuisa Lavitrano and Emanuela Grassilli contributed equally to this work
and should be considered co-corresponding authors.
1Department of Medicine and Surgery, University of Milano-Bicocca, Monza,
Italy
Full list of author information is available at the end of the article
Giordano et al. Journal of Experimental & Clinical Cancer Research          (2019) 38:260 
https://doi.org/10.1186/s13046-019-1199-7
(Continued from previous page)
Conclusions: p65BTK results as an emerging actionable target in non-smoking EGFR-wt AdC, also at advanced stages
of disease. Notably, these patients are not eligible for EGFR-TKIs-based therapy due to a lack of EGFR mutation. The
combination of BTK-TKIs with EGFR-TKIs is cytotoxic for EGFR-wt/KRAS-mutant/p53-null tumors and BTK-TKIs re-
sensitizes drug-resistant NSCLC to SOC chemotherapy. Therefore, our data suggest that adding BTK-TKIs to SOC
chemotherapy and EGFR-targeted therapy may open new avenues for clinical trials in currently untreatable NSCLC.
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Background
Lung cancer accounts for about 28% of all cancer-related
deaths worldwide and represents the number one killer
cancer [1]. Moreover, the majority of cases are diagnosed
at advanced stages of disease, thus inadequate for surgery
[2, 3]. The main histotype is non-small cell lung cancer
(NSCLC; 85% of cases), which in turn comprehends
adenocarcinomas (AdC), squamous cell (SCC) and large
cell (LCC) carcinomas [4].
In the evolution toward a more personalized and efficient
therapeutic approach, particular emphasis is on the under-
standing of lung cancer biology and on the consequent
identification of new actionable targets in order to develop
a tailored medicine. Indeed, significant improvements have
been achieved in molecular characterization of NSCLC, in
particular of AdC. The most frequent driver mutations
occur in receptors or protein kinases related to RAS/
MAPK, PI3K/AKT/mTOR and JAK/STAT pathways, all of
which eventually result in hyper-activation of the MAPK
signaling [5, 6]. In particular, the most commonly mutated
genes are, p53, KRAS, epidermal growth factor receptor
(EGFR), mesenchymal epithelial transition factor (MET)
and anaplastic lymphoma kinase (ALK) [7]. The definition
of the mutational landscape of NSCLC has allowed the
identification of actionable cancer genes such as EGFR,
ALK, ROS1, BRAF and the development of targeted ther-
apies [7]. Nevertheless, the percentage of patients without
alterations in actionable genes is > 40% [8], making those
patients inadequate for targeted therapy. Moreover, despite
mutated KRAS is one of the most frequent (31%) alteration
in NSCLC, it represents an unmet clinical need since no
specific inhibitor has successfully progressed through clin-
ical trials so far [9]. Notably, mutations in KRAS are mutu-
ally exclusive with EGFR mutations and are associated with
severe prognosis and resistance to chemotherapy or EGFR
inhibitors [10–12]. Finally, tumour primary or acquired re-
sistance to target therapy regimens and even to chemother-
apy severely impacts on NSCLC progression and patients’
prognosis [6, 13]. In this scenario, alternative molecular tar-
gets downstream of KRAS are urgently needed.
Bruton tyrosine kinase (BTK) is a 77 kDa non-receptor
tyrosine kinase that plays a crucial role in B-cell activa-
tion, proliferation, maturation, differentiation and sur-
vival [14]. BTK has emerged as a novel molecular target
in some B-cell leukemias and lymphomas where it is
commonly overexpressed [15]. Accordingly, Ibrutinib,
the first irreversible BTK inhibitor, has been recently ap-
proved by the FDA for the treatment of certain B-cell
malignancies [16]. This has led to a rapid development
in the field and several other BTK inhibitors, among
which AVL-292 (Spebrutinib), are currently in advanced
phase of clinical trial for different types of leukemia [17].
Recently, our lab identified and characterized p65BTK, a
novel isoform of BTK, overexpressed in colon cancers. Not-
ably, in this tissue only the messenger encoding p65BTK
and not that for p77 is expressed [18]. Interestingly,
p65BTK expression and abundance are post- transcription-
ally regulated by the MAPK pathway and the protein acts
downstream of KRAS. In addition, p65BTK is an obligate
effector of RAS-mediated transformation [18], making it an
attractive therapeutic target for KRAS-mutated cancers. To
define a novel possible druggable target in cases currently
not treatable with available targeted therapies, we investi-
gated p65BTK expression in NSCLC studying the biological
effects of its inhibition alone or in combination with SOC




A previously described series of 383 chemo- and/or
radio-naïve NSCLC patients who underwent surgery for
therapeutic purposes at Fondazione IRCCS Ca′ Granda-
Ospedale Maggiore Policlinico Hospital (Milan, Italy) be-
tween 2004 and 2010 [19] was used to investigate p65BTK
expression and correlation with patients’ clinic-pathological
features. In addition, metastatic lymph nodes from 30
NSCLC patients were retrieved and analysed.
Patients’ informed consent was obtained and the
study was approved by the Fondazione IRCCS Ca′
Granda Institutional Review Board (Institutional Re-
view Board 179/2013). Data were analysed anonym-
ously. Clinico-pathological records were available for
the entire cohort whereas smoking habits was avail-
able for 348 patients. Moreover, the presence of ALK
rearrangements or EGFR mutations was analysed for
all cases as described [19]. Patients’ features are
described in Additional file 1: Table S1.
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Antibody production and characterization
BN30 polyclonal antibody was obtained in rabbits by
immunization with the N-terminal decapeptide of
p65BTK, conjugated to keyhole limpet hemocyanin via an
additional C-terminal cysteine residue and validated as
follows: specificity of BN30 polyclonal antiserum (IgG
fraction), used for IHC, was assessed by western blot ana-
lysis on lysates of SW480 cells transfected with control
(luc) or p65BTK-specific siRNA and by immunocyto-
chemistry, on sections from cell blocks of SW480
p65BTK-expressing and p65BTK-silenced cells (Add-
itional file 1: Figure S1a, b). Moreover, its specificity was
assessed also by western blot analysis on lysates of SW480
cells transfected with control (luc) or p65BTK-specific
siRNA vs lysates from the lymphoblastic leukemia cell line
Nalm-6 which express p77BTK together with low levels of
p65BTK (Additional file 1: Figure S1c) [18].
Tissue microarray (TMA) construction and
immunohistochemical (IHC) staining
Representative tissue blocks of tumour and non-neoplas-
tic lung tissue derived from each patient were used to
construct TMAs, as previously described [20]. Briefly,
for all lung cancer samples five representative cores were
selected by a pathologist whereas for non-neoplastic par-
enchyma one core was chosen. Metastatic lymph nodes
of NSCLC patients were analysed as well (n = 30) as full
sections. For all blocks, 4-μm-thick sections were cut
and subjected to IHC staining for p65BTK using the
above described BN30 antibody in a BenchMark Ultra
automatic system (Ventana Medical Systems). Reactions
were revealed using the UltraView Universal DAB, ac-
cording to the manufacturer’s instructions (Ventana
Medical Systems) and all slides were counterstained with
hematoxylin. As positive control we used a colon carcin-
oma specimen, whereas negative controls were prepared
in the absence of primary antibody and included in each
reaction. p65BTK cytoplasmic staining was evaluated
and scored in all cases, by two pathologists independ-
ently, as percentage of positive neoplastic cells in all
tumour cores or in the whole section (for metastatic
lymph nodes).
Cell lines, culture, and treatments
All commercial human NSCLC cell lines used were from
ATCC. The mutational background of the four cell lines
used for the in vitro experiments is reported in Table 2.
Mouse lung cancer primary cell lines were from Silve
Vicents’ lab [21]. Upon reception, cells were expanded
and frozen as seed stocks of first or second passage. All
cells were passaged for a maximum of 3 or 4 weeks, after
which new seed stocks were thawed for experimental
use. All cells were grown at 37 °C in 5% CO2 and were
maintained as a sub confluent monolayer using the fol-
lowing media: Dulbecco’s modified eagle’s medium
(DMEM) for SK-LU-1 and Calu-6 supplemented with
non-essential amino acids (NEAA) and 1% sodium
pyruvate; Roswell Park Memorial Institute 1640
(RPMI 1640) supplemented with 1% sodium pyruvate
for NCI-H1975 and NCI-H2228. Mouse lung cancer
primary cell lines were grown in DMEM. In addition,
all media were also supplemented with 10% fetal bo-
vine serum and 1% penicillin-streptomycin. Media,
serum, and supplements were all from Invitrogen.
BTK inhibitors Ibrutinib, AVL-292, RN486 and EGFR
inhibitors Erlotinib and Gefitinib and MEK inhibitor
Trametinib (all inhibitors were purchased from Sell-
eckchem), were dissolved in DMSO and stored in ali-
quots at − 80 °C. Chemotherapeutic drugs Cisplatin,
Pemetrexed and Gemcitabine were kindly provided by
S. Gerardo Hospital (Monza). Caspase inhibitor
QVD-OPh was Sigma-Aldrich.
Western blot analysis
Protein extracts were prepared using high-salt lysis buffer
(50mM Hepes (pH 7.5), 500mM NaCl, 1mM DTT, 1mM
EDTA, 0.1% NP-40) supplemented with 1% protease inhibi-
tor cocktail (Sigma-Aldrich). 20 μg of cell lysates were sepa-
rated on 10% tris-glycine Wedge-wells gels (Invitrogen),
transferred onto a nitrocellulose membrane (Invitrogen) and
incubated with the following antibodies: anti-p65BTK BN49
[18]; anti-Actin (#A1978, Sigma-Aldrich); anti-vinculin
(#V9131, Sigma-Aldrich); anti-pERK (#4370, Cell Signaling
Technology); BTK(#611117, Becton Dickinson). Purified
p77BTK (#B4312) was from Sigma-Aldrich. Images were ac-
quired using G:BOX XT4 Chemiluminescence and Fluores-
cence Imaging System (Syngene) and processed with Adobe
Photoshop.
Cell proliferation/viability assay
Cells were seeded in 96-well plate at 70% confluency in
octuplicates for overnight attachment. For survival
curves, cells were treated with the different concentra-
tions of inhibitors (day 0) and cell number was evaluated
after 72 h using an MTT-based assay (Sigma-Aldrich)
according to the manufacturer’s instructions. For growth
curves, 3000 cells were seeded and their number was
evaluated at 0, 24, 48 and 72 h by crystal violet staining.
Briefly, after washing with PBS, cells were fixed with
Formalin 10% (Bio-Optica) for 1 h on the shaker and
then stained with a crystal violet solution (Sigma-Al-
drich) in 35% ethanol (Sigma-Aldrich) for 20 min at
room temperature. After washing extensively with tap
water, color was extracted by adding 0.1M acetic acid
and quantified by spectrophotometer at 595 nm. Graphs
represent the average of 3 to 5 independent experiments.
Average ± s.e.m. are plotted in the graphs.
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Cell toxicity assay
Cells were seeded in octuplicates at 70% confluency and
the next morning treated or not with drugs and inhibi-
tors and their combination as indicated in the figures.
Cell viability was evaluated by CellTiter-Glo® Lumines-
cent Cell Viability Assay (Promega) following manufac-
turer’s instructions. Graphs represent the average of 3 to
5 independent experiments. Average ± s.e.m. are plotted
in the graphs.
Analysis of synergy
Combination Index (CI) was calculated as reported by
Fransson et al. [22]. Predicted cell viability (PCV) (%)
was calculated according to the following formula: PCV
(%) = cell viability after treatment with drug 1 (%) x cell
viability after treatment with drug 2 (%) × 0.01. CI was
then derived as the ratio of the measured cell viability of
the cells incubated with both drugs /PCV. 0.8 < CI <
1.2 = additive effect (the interval of 1.0 ± 0.2 is set to ac-
count for intra-assay variability); CI < 0.8 = synergistic ef-
fect; CI > 1.2 = sub-additive effect. If the measured cell
viability for a combination of two drugs is higher than
the cell viability for one or both of the drugs, the effect
is considered antagonistic. CI < 0.5 has been considered
as a strong synergistic effect.
Caspase assay
2 × 104 cells/well were seeded in triplicate in 96-well
plates, let adhere overnight, and treated for 24hs before
evaluating active caspase-3/7 by Caspase-Glo3/7 Assay
System (Promega, Milan, Italy) according to the manu-
facturer’s instructions. Assays were repeated 3 times for
each time point (n = 3).
Colony forming assay
Cells were seeded at low density (1000 cells/well in
6-well plate) in triplicate and left untreated or treated
with different concentrations of Ibrutinib, AVL-292 and
RN486. Medium (alone or supplemented with the inhib-
itors) was replaced every 3 days. After 10 days, colonies
were fixed and stained with 1% crystal violet in 35%
ethanol. Images were acquired using G:BOX XT4
Chemiluminescence and Fluorescence Imaging System
(Syngene, Cambridge, UK) and processed with Adobe
Photoshop. Colony assays were repeated 3 times.
Immunofluorescence staining
NSCLC cell lines were seeded at a density of 10× 105
cells/well on glass slides pretreated with Polylysine
(Sigma) and grown for 2 days. After treatments cells
were washed with PBS and fixed for 10 min in 1.6%
Paraformaldehyde (Sigma-Aldrich) and washed again
with PBS. The slides were then permeabilized with
ice-methanol at − 80 °C overnight. The day after, slides
were incubated with anti-pBTK tyr551 (1:100 in 3% BSA
in PBS; Bioss) for 1 h at room temperature and then
washed 3 times with PBS. Then, the slides were incu-
bated with secondary antibodies diluted 1:2000 in 3%
BSA in PBS for 40 min at room temperature, washed 3
times with PBS and evaluated using a fluorescence
microscope (Zeiss, Germany). Nuclei were counter-
stained with DAPI (Sigma-Aldrich).
Statistical analysis
Data were analyzed using unpaired t test with or
without Welch correction unless otherwise specified.
A probability (p) value less than 0.05 was considered
as statistically significant.
Results
p65BTK is overexpressed in advanced lung
adenocarcinomas with wild type EGFR from never-smoker
patients
Using the BN30 isoform-specific polyclonal antibody
we previously developed and characterized in the lab
we examined p65BTK expression in cancer tissues de-
rived from a cohort of chemo- and/or radio-naïve
NSCLC patients (Additional file 2: Table S1). To this
end, 382 out of 383 cases were available. Overall,
p65BTK was expressed in 51% of NSCLC (Table 1).
Interestingly, p65BTK was more expressed in AdC
than in SCC cases (p < 0.0001; Fig. 1a and b, Table 1).
Table 1 p65BTK score of the NSCLC patients’ tissue analyzed by IHC
p65BTK expression All (382) AdC (293) SCC (89) Smokers (283) Non-smokers (65)
Negative 189 (49.3%) 129 (43.9%) 60 (67.4%) 151 (53.3%) 18 (27.7%)
1–10% positive cells 131 (34.2%) 106 (36%) 25 (28.1%) 101 (35.7%) 21 (32.3%)
11–20% positive cells 12 (3.1%) 10 (3.4%) 2 (2.2%) 5 (1.8%) 5 (7.7%)
21–50% positive cells 24 (6.3%) 23 (7.8%) 1 (1.1%) 15 (5.3%) 8 (12.1%)
51–100% positive cells 26 (6.8%) 25 (8.5%) 1 (1.1%) 11 (3.9%) 13 (20%)
Positive 193(50.4%) 164 (55.8%) 29 (32.6%) 132 (46.7%) 47 (72.3%)
The analysis was performed on TMA using the antibody BN30, produced and characterized in the lab. AdC adenocarcinoma, SCC squamous cell carcinoma
In bold are indicated the number of samples completely negative or positive (any positivity) for p65BTK expression
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Within AdC patients, the protein’s levels were signifi-
cantly higher in never-smokers and in EGFR-wt tu-
mors (p < 0.0001; Fig. 1c and d, Table 1). Conversely,
no difference was observed according to ALK trans-
location (Additional file 3: Figure S2). When we ana-
lyzed p65BTK expression according to nodal status of
NSCLC patients, we found that tumor from patients
with distant nodal metastases (e.g., pN2) expressed
higher levels of the protein than tumors with
loco-regional or no nodal involvement (pN1 and pN0,
respectively) (Fig. 1e). Finally, p65BTK expression was
present also in nodal metastases at levels comparable
to the primary tumour (Fig. 1f ). Interestingly,
p65BTK staining was observed in in both cancer cells
and tumor-infiltrating lymphocytes (TILs) in the
lymph nodes metastasis. It is known that than 80% of
TILs is represented by T cells [23] and that p77BTK
is not expressed in the T cell lineage [14]. We showed
that p65BTK is expressed in T cells lysates from
FACS-purified T cells using BN49 antibody (Add-
itional file 4: Figure S3), thus suggesting that in the
nodal metastases the reactivity was due to expression
of p65BTK. Overall, these data suggest that p65BTK
could be a novel target in advanced NSCLC from
Fig. 1 p65BTK is overexpressed in advanced lung adenocarcinomas with wild type EGFR from never-smoker patients. a IHC analysis of p65BTK in
lung cancer tissue samples from a cohort of NSCLC patients using the BN30 antibody. Representative images of normal lung and lung cancer
tissues are shown. SCC: squamous cell carcinoma; AdC/S: adenocarcinoma from smoker patient; AdC/NS: adenocarcinoma from non-smoker
patient. Scale bar 100 μM. b Quantification of p65BTK expression in SCC and AdC patients. ***, p < 0.0001 by unpaired t test with Welch’s
correction. c Quantification of p65BTK expression in smoker and non-smoker patients AdC and SCC patients. NS: non-smoker; S: smoker.
Quantification of p65BTK expression. d Quantification of p65BTK expression in smoker and non-smoker AdC patients with either wild type (WT) or
mutated (MT) EGFR. *, p = 0.04; ***, p < 0.0001 by non-parametric t test. e Quantification of p65BTK expression in primary NSCLC according to pN
status. *, p = 0.04 by unpaired t test with Welch’s correction. f IHC analysis of p65BTK in metastatic lymph nodes of lung adenocarcinomas (AdC)
or squamous cell carcinoma (SCC). Representative images show different expression levels of the kinase in the metastatic setting. Scale bars
500 μm (top panels) or 200 μm (lower panels)




Fig. 2 NSCLC cells with activated KRAS express high levels of p65BTK. a Top: Western Blot analysis of p65BTK expression in NSCLC human cell
lines with different mutations along the RAS/MAPK pathway and in p53. Lysate from HCT116p53KO colon cancer cells was loaded as a positive
control. Bottom: fold change of p65BTK protein expression in NSCLC cell lines normalized to beta actin, setting as expression level = 1 NCI-H1935
which do not possess mutations in KRAS or in the RAS/MAP pathway not in the p53 gene. b Top: Western Blot analysis of p65BTK expression in
primary lung cancer cells derived from KrasLSL-G12D (LKR10, LKR13, LSZ1) and KrasLSL-G12D;Trp53f/f (389 N1, 482 N1) mice. UNSCC680 is a primary
cell line from a mouse squamous cell carcinoma. Bottom: fold change of p65BTK protein expression normalized to beta actin. In a and b p65BTK
was detected by BN49 antibody [18] and beta actin was used as a loading control. c IHC analysis of p65BTK in normal and tumoral lung tissue
samples from 2 different KrasLSLG12D; Trp53 f/f mice using BN30 antibody. d Left: Western Blot analysis of p65BTK expression in SK-Lu-1 and NCI-
H2228 cells after treatment with the MEK inhibitor Trametinib (1 μM). Right: fold change of p65BTK protein expression normalized to vinculin
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EGFR-wt non-smokers that are not eligible for tar-
geted therapy.
NSCLC cells with activated KRAS express high levels of
p65BTK
We then analysed p65BTK expression in NSCLC cell
lines. By using the BN49 isoform-specific polyclonal anti-
body that we previously developed and characterized [18],
we showed that p65BTK was abundantly expressed at the
protein level by several NSCLC cell lines with a mutation
in KRAS or in the RAS/MAPK pathway (Fig. 2a). In par-
ticular, the highest levels of p65BTK were expressed by
cell lines with both a p53 mutation and a mutation in
KRAS or in the RAS/MAPK pathway. The highest ex-
pressing cell lines, ie KRAS-mutated Calu-6 and SK-Lu-1,
EGFR-doubly mutated NIH-H1975, and ALK-translocated
NIH-H2228 were analysed by qPCR for p65BTK and
p77BTK expression. Interestingly, only p65BTK-encoding
transcript was expressed by all cell lines (Additional file 5:
Table S2), confirming our previous data from colorectal
carcinoma [18].
p65BTK was overexpressed in primary cell lines (LKR10
and LKR13) (Fig. 2b) derived from tumors spontaneously
arising in KrasLSL-G12D mice, a genetically engineered
mouse model of Kras-driven lung cancer [24]. Notably, its
expression was increased in primary cell lines (389N1 and
482N1) derived from tumors of KrasLSL-G12D;Trp53f/f
mice (Fig. 2b), where p53 inactivation accelerates AdC
progression in a Kras-mutated context [24]. Remarkably,
compared with non-neoplastic tissue, p65BTK was uni-
formly and highly expressed in tumor samples from Kras
LSL-G12D;Trp53f/f mice (Fig. 2c).
Finally, accordingly to what we previously reported
for colon cancer cells [18] we confirmed that p65BTK
expression is regulated by the activation of the RAS/
MAPK pathway by showing that its expression, as
well as its activation, is down-regulated upon the
treatment of NSCLC cells with Trametinib, a MEK
inhibitor (Fig. 2d).
These results confirm what observed in NSCLC pa-
tients and our previous data on colorectal cancer [18],
regarding the preferential up-regulation of p65BTK in a
context of RAS/MAPK hyper-activation. Moreover, these
data show that high p65BTK expression correlates with
advanced lung cancer.
p65BTK targeting affects cell viability of NSCLC cell lines
and tumor-derived primary cells scarcely responsive to
EGFR inhibition
To investigate whether p65BTK could be a novel target
in advanced NSCLC, we firstly evaluated whether
p65BTK was constitutively activated in NSCLC cell lines
with different mutations along the EGFR/RAS/MAPK
pathway (Table 2). To this end, we checked the activa-
tion of p65BTK analysing its phosphorylation in Y465.
This tyrosine residue corresponds to Y551 in p77BTK,
whose phosphorylation reflects its activation [25]. Our
results indicated that in all the cell lines expressing high
levels of p65BTK the kinase was constitutively active
(Additional file 6: Figure S4, panel a, b) and its activation
was dampened by BTK inhibitors (Additional file 7: Fig-
ure S4, panel c, d). We also tested the effects of EGFR
inhibition in the same cell lines by treating them with
increasing concentrations of the two specific first
generation EGFR-TKIs currently used in therapy, Erloti-
nib and Gefitinib (Fig. 3a). After 72 h, only a
dose-dependent reduction of cell number but no
cytotoxic effects were observed. The same results were
confirmed in tumor-derived primary cell lines from
KrasLSL-G12D (LKR10 and LKR13) and KrasLSL-
G12D;Trp53f/f (389 N1 and 482 N1) mice (Fig. 3b).
Next, we tested the effect of BTK inhibitors (Ibruti-
nib, AVL-292 and RN486) in the same cell lines and
we found that p65BTK inhibition resulted in a stron-
ger anti-proliferative effect than the treatment with
EGFR inhibitors. In fact, a significant reduction in cell
number was observed even at lower doses of BTK in-
hibitors, among which RN486 showed even cytotoxic
effects in all cell lines when used at the highest con-
centration (Fig. 4a and b).
These results indicate that cell lines bearing mutations
in the EGFR/RAS/MAPK pathway are very sensitive to
p65BTK inhibition.
Table 2 Known genetic alterations characterizing the NSCLC lines used in the paper. Information about genetic defects were
retrieved from the database of the Wellcome Trust Sanger Institute Catalogue Of Somatic Mutations In Cancer COSMIC, https://
cancer.sanger.ac.uk/cell_lines)
Cell line Hystotype Mutational status
TP53 EGFR KRAS Other mutations/molecular alterations
Calu-6 anaplastic carcinoma mut wt Q61K JAK1, BRCA1, p16INK4A methylation
SK-Lu-1 adenocarcinoma mut wt G12D KIT, CSF3R, FLT4
NCI-H1975 adenocarcinoma mut L858R + T790 M wt PDGFRA, PIK3CA
NCI-H2228 adenocarcinoma mut wt wt ALK translocation, PDGFRA, RB
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p65BTK inhibition strongly impairs proliferation and
clonogenicity of NSCLC cell lines
Given the significant reduction in cell number obtained
with BTK inhibitors, we then investigated the effects of
p65BTK inhibition on cell proliferation and clonogenicity
of NSCLC cell lines. First, we performed growth curves of
NSCLC cell lines in the presence of increasing concentra-
tions of p65BTK inhibitors and observed that p65BTK in-
hibition strongly impaired proliferation of all NSCLC cell
lines. As shown in Fig. 5a, in all the cell lines analysed,
10 μM Ibrutinib caused a slight to moderate decrease of
proliferation whereas a strong decrease was observed only
at the highest dose of Ibrutinib (20 μM). AVL-292 and
RN486 instead strongly decreased cell proliferation when
used at concentrations as low as 5 μM (Fig. 5a).
Moreover, we investigated whether p65BTK inhibition
could affect the clonogenicity of NSCLC cell lines by
evaluating colonies growth in the presence of increasing
concentrations of p65BTK inhibitors. Our results indi-
cated that Ibrutinib was able to reduce colony formation
only at the highest dose (20 μM), whereas AVL-292 and
RN486 were efficient already at lower concentration
(5 μM) (Fig. 5b). In particular, NCI-H1975 and
NCI-H2228 cell lines, bearing a double mutation in the
EGFR and an ALK translocation respectively, resulted
more sensitive to all the inhibitors tested (Fig. 5b).
All together these data show that p65BTK inhibition
impairs proliferation and clonogenicity of NSCLC cell
lines, being AVL-292 and RN486 effective at low
concentration.
p65BTK inhibition sensitizes NSCLC cell lines scarcely
responsive to target therapy and chemotherapy
independently of the EGFR and KRAS status
Next, we tested whether the addition of Ibrutinib,
AVL-292 and RN486 could sensitize cells to EGFR in-
hibitors (Fig. 6). We showed that the combination of
EGFR inhibitors and BTK inhibitors had a strong syner-
gistic effect in most cases (Table 3). In particular, the
combination of 20 μM Ibrutinib and 20 μM Gefitinib
was highly cytotoxic for all the NSCLC cell lines scarcely
responsive to EGFR inhibition. Whereas, the combin-
ation of 20 μM Ibrutinib with 20 μM Erlotinib was cyto-
toxic only for NCI-H1975 cells (which bear L858R +
T790M EGFR mutations). The combination of 10 μM
AVL-292 with 20 μM Gefitinib was cytotoxic in SK-Lu-1
and Calu-6 cells, cytostatic in NCI-H1975 cells and inef-
fective in NCI-H2228 cell. On the contrary, the combin-
ation of 10 μM AVL-292 and 20 μM Erlotinib was mildly
cytotoxic only in the NCI-H1975 cells. 10 μM RN486 in
combination either with 20 μM Gefitinib or 20 μM Erlo-
tinib was cytotoxic in all the cell lines.
We then studied the effect of combining p65BTK inhib-
itors with SOC chemotherapy agents currently used in the
clinic such Cisplatin, Pemetrexed and Gemcitabine, also
in this case the combination of the different BTK inhibi-
tors and chemotherapeutic drugs was mostly strongly syn-
ergistic (Table 4). In fact, the combination of RN486 with
any of these drugs dramatically reverted the chemo-resist-
ance in all the cell lines analysed. The co-treatment Ibruti-
nib/Cisplatin was cytotoxic only in SK-Lu-1 and
NCI-H1975 cells whereas it had a cytostatic effect in
Calu-6 and NCI-H2228 cells. The combination of Ibruti-
nib with Pemetrexed or Gemcitabine was ineffective. Fi-
nally, the combination of AVL-292 with SOC drugs had a
stronger anti-proliferative effect than each of the drugs ad-
ministered alone in all cell lines (Fig. 7).
Finally, we determined that the cytotoxicity observed
when combining p65BTK inhibition with EGFR inhib-
ition or SOC therapy was due to induction of apoptosis
as demonstrated by caspase activation and protection
from cell death upon addition of the pan-caspase inhibi-
tor QVD-OPh (Additional File 7: Figure S5).
Overall, the inhibition of p65BTK in combination with
the EGFR-TKIs or chemotherapeutic drugs is effective in
sensitizing NSCLC cells scarcely responsive to the
current treatments, even if different inhibitors show or
not synergy depending on which EGFR inhibitor or che-
motherapeutic drug they are combined with.
Discussion
In the last decade, significant advances at the molecular
level have afforded an improved understanding of the
underlying pathology and significant biological hetero-
geneity of NSCLC. Multiple signalling pathways have
now been identified, as well as specific oncogenic driver
mutations that lead to malignant transformations. In-
deed, a number of clinical series has been profiled for
the identification of key actionable alterations [6]. Des-
pite the continuous discoveries in cancer treatment, the
problem of the primary or acquired resistance is still un-
solved. Therefore, it is of particular importance the
(See figure on previous page.)
Fig. 3 EGFR inhibition does not affect cell viability of NSCLC cell lines and tumor-derived primary cells with mutations along the EGFR/RAS/MAPK
pathway. Dose-response curves of a human NSCLC cell lines (SK-Lu1, Calu-6, NCI-H1975 and NCI-H2228) and b primary lung cancer cell lines
derived from KrasLSL-G12D (LSZ1, LKR13) and KrasLSL-G12D;Trp53f/f mice, (389 N1, 482 N1) treated with increasing concentrations of EGFR inhibitors
(Erlotinib and Gefitinib). Cell viability was evaluated by MTT assay. X-axis crosses in correspondence of T0 values (before starting the treatment);
72 h values are then expressed as the variation relative to the initial cell number. Scale on Y-axis is adapted to the different growth rates shown
by each cell line. Data are presented as mean ± SEM. n≥ 3 independent experiments
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ab
Fig. 4 p65BTK targeting affects cell viability of NSCLC cell lines and tumor-derived primary cells scarcely responsive to EGFR inhibition. Dose-
response curves of a human NSCLC cell lines (SK-Lu1, Calu-6, NCI-H1975 and NCI-H2228) and b primary lung cancer cells derived from KrasLSL-
G12D (LSZ1, LKR13) and KrasLSL-G12D;Trp53f/f mice (389 N1, 482 N1) treated with increasing concentrations of BTK inhibitors (Ibrutinib, AVL-292,
RN486). Cell viability was evaluated by crystal violet staining. X-axis crosses in correspondence of T0 values (before starting the treatment); 72 h
values are then expressed as the variation relative to the initial cell number. Scale on Y-axis is adapted to the different growth rates shown by
each cell line. Data are presented as mean ± SEM. n≥ 3 independent experiments
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identification of new molecular targets to overcome drug
resistance of NSCLC.
Here we report that p65BTK is an emerging actionable
target in NSCLC cells resistant to chemotherapy and
scarcely responsive to target therapy. We previously dem-
onstrated that BTK is an actionable target in KRAS-mu-
tated colon cancer [18]. In this study we extended this
observation to NSCLC and particularly to AdC and
showed that p65BTK levels were significantly higher in
EGFR-wt tumours from never-smoker patients and in
tumour with metastasis at distant nodal stations (Fig. 1).
Moreover, nodal metastases from NSCLC retained
p65BTK expression, claiming a role for p65BTK also in
advanced stage of disease. We confirmed that only
p65BTK, and not p77BTK, was expressed in NSCLC
(Additional file 5: Table S2) and we showed that p65BTK
over-expression correlated with mutations in KRAS or the
RAS/MAPK pathway both in in vitro and in vivo models
of lung cancers with mutated KRAS (Fig. 2).
Importantly, BTK inhibition significantly hampered
cell proliferation and clonogenicity in all the cells lines
with hyper-activation of the MAPK pathway deriving
a
b
Fig. 5 p65BTK inhibition strongly impairs proliferation and clonogenicity of NSCLC cell lines. a Growth curves of human p53-null NSCLC cell lines
treated with increasing concentrations of BTK inhibitors; cell number was evaluated each 24 h by MTT assay. Scale on Y-axis is adapted to the
different growth rates shown by each cell line. Data are presented as mean ± SEM. n≥ 3 independent experiments. * indicates p < 0.05 vs
untreated. b Clonogenicity assay of human p53-null NSCLC cell lines treated with increasing concentrations of BTK inhibitors for 10 days. A
representative image of one experiment out of 3 is shown
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from different genetic defects, such as a double mutation
L858R/T790M in the EGFR (NCI-H1975), an ALK
translocation (NCI-H2228) or a mutation in KRAS
(SK-Lu-1 and Calu-6) (Figs. 3, 4, 5). Moreover, BTK in-
hibition re-sensitized lung cancer cells to either
EGFR-targeted (Fig. 6) or SOC chemo-therapies (Fig. 7)
disregarding EGFR/KRAS mutational status.
Recently we demonstrated that p65BTK, a new onco-
genic isoform of BTK different from the already known
77 kDa isoform, is highly expressed in colon cancer
cells and tissues. We also demonstrated that BTK onco-
genic activity is mediated only by the p65 isoform, and
that p65BTK acts downstream of the RAS/MAPK path-
way. In fact, p65BTK transforming activity depends on
active signal-regulated protein kinases-1/2 (ERK1/2)
and on RAS activity. Accordingly, p65BTK
over-expression in colon cancer tissues correlates with
ERK1/2 activation and its inhibition decreases cell
growth and survival of colon cancer cells [18]. Here we
confirm that, also in NSCLC, p65BTK expression level
depends on the RAS/MAPK pathway activation (Fig.
2d) and that p65BTK inhibition strongly affect cell pro-
liferation and survival (Figs. 4 and 5). Altogether, data
from colorectal cancer and NSCLC suggest that
p65BTK is an emerging actionable target in tumour
cells resistant to chemotherapy and scarcely responsive
to target therapy because of lack of EGFR mutation or
presence of activated KRAS [26, 27]. Notably, despite
KRAS mutation is one of the most prevalent oncogenic
driver mutations in NSCLC (up to 31%), its targeting
remains elusive, mainly because of the lack of mole-
cules able to successfully pass the clinical trial step
[28]. Indeed, there are no effective therapeutic ap-
proaches toward mutated KRAS and the possibility of
targeting a downstream effector of KRAS, such as
p65BTK, would therefore represent an alternative strat-
egy for overcoming this main limitation.
BTK has been for long time considered to be exclu-
sively expressed in hematopoietic cells, where it is
crucial for B cell maturation and proliferation and for
monocyte/macrophage activation [14]. BTK inhibitors
were developed for the treatment of
Fig. 6 p65BTK inhibition sensitizes NSCLC cell lines scarcely
responsive to EGFR-targeted therapy. Cell viability of human p53-null
NSCLC cell lines in response to different combinations of BTK and
EGFR inhibitors (T0 = time 0; NT = untreated; GEF20 = Gefitinib 20 μM;
ERL20 = Erlotinib 20 μM. IBRU20 = Ibrutinib 20 μM; AVL10 = AVL-292
10 μM; RN10 = RN486 10 μM). X-axis crosses in correspondence of T0
values (before starting the treatment); 72 h values are then
expressed as the percentage variation relative to the initial cell
number. Scale on Y-axis is adapted to the different growth rates
shown by each cell line. Data are presented as mean ± SEM. n ≥ 3
independent experiments. * indicates p < 0.05 vs T0 values
Table 3 Synergism between BTK and EGFR inhibitors
Ibrutinib AVL-292 RN486
Gefitinib Erlotinib Gefitinib Erlotinib Gefitinib Erlotinib
Calu-6 0.04 0.20 0.18 0.18 0.13 0.10
SK-Lu-1 0.02 0.20 0.13 0.17 0.11 0.11
NCI-H1975 0.01 0.01 0.74 0.26 0.34 0.17
NCI-H2228 0.01 ant ant ant 0.18 0.11
Combination Index (CI) was calculated as reported by Fransson (Fransson, A.,
et al. (2016) J Ovarian Res 9 [1]: 27) and detailed in material and methods
0.8 < CI < 1.2 = additive effect, CI < 0.8 = synergistic effect (CI < 0.5 = strong
synergistic effect), CI > 1.2 = sub-additive effect, ant = antagonistic effect
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lymphoproliferative disorders: among them Ibrutinib
is already FDA-approved for the treatment of mantle
cell lymphoma, chronic lymphocytic leukemia and
Waldenström macroglobulinemia. On the contrary,
other BTK inhibitors, such as AVL-292, are in clinical
trials for different hematological malignancies such as
several B-cell leukemias/lymphomas, myelomas and
acute myelogenous leukemia, and autoimmune dis-
eases [29]. However, in recent years a number of re-
ports demonstrated the expression of BTK in solid
tumors and showed promising results by its inhibition
with Ibrutinib [30–32]. Even though in many cases
(such as glioma and glioblastoma, oesophageal and
gastric cancers, renal cell and ovarian carcinoma) the
isoform of the BTK expressed was not fully investi-
gated and has been assumed to be p77, other reports
pointed out the existence of different isoforms [32].
Due to their established effect on multiple
tumour-related kinases such as the EGFR family mem-
bers [33], Ibrutinib and AVL-292 have been experimen-
tally proved useful in solid cancers such as glioblastoma,
lung and breast carcinomas [34–39] and are now in clin-
ical trials for EGFR-mutated NSCLC (https://clinical-
trials.gov/ct2/show/NCT02321540?term=ibrutinib&cond
=NSCLC&rank=2) and HER2-amplified metastatic breast
cancer (https://clinicaltrials.gov/ct2/show/NCT03379428?
ter=ibrutinib&cond=Breast+Cancer&rank=1). Specifically,
Ibrutinib and AVL-292 are two irreversible inhibitors that
target the same critical Cys481 residue in the kinase do-
main [40, 41], a residue conserved also in the EGFR family
members. Previous reports described an anti-proliferative
or pro-apoptotic effect of Ibrutinib in EGFR-mutated
NSCLC cells [34–36] that was attributed to the inhibition
of mutated EGFR by Ibrutinib. Among those, Gao et al.
[34] investigated BTK expression in NSCLC cell lines
(among which NIH-H1975) and they did not detect
p65BTK probably because they used a commercial
antibody raised against the p77 isoform. Therefore,
the authors did not address the inhibition of BTK by
Ibrutinib. In contrast, our data indicate that the effect
of Ibrutinib in NSCLC is due to p65BTK inhibition
for several reasons: i) we strengthened and confirmed
our results on the biological effects of p65BTK
inhibition with two other inhibitors (AVL-292 and
RN486), one of which has a different mechanism of
action (see below); ii) all the BTK-TKIs we tested
have an anti-proliferative activity independently of the
EGFR mutational status in NSCLC cells (Figs. 4, 5) in
contrast with the fact that Ibrutinib binds only mu-
tant, and not wt EGFR [36]; iii) BTK-TKIs showed a
synergic effect with EGFR-TKIs turning a mild
anti-proliferative effect in a cytotoxic one (Fig. 6). In
particular, the synergistic effect of such combination
may be explained by the fact that the inhibitors act at
different levels of the pathway downstream the EGFR
and p65BTK acts downstream of the RAS/MAPK
cascade.
Notably, given that our data show that only the p65
isoform is expressed in lung cancer cells and tissues,
a p65BTK specific antibody should be used to identify
potential NSCLC patients candidate for anti-BTK
therapy.
Finally, our in vitro results indicate that among the
BTK inhibitors RN486 is more powerful than Ibrutinib
and AVL-292 in blocking lung cancer cell proliferation
and sensitizing drug-resistant NSCLC cells to either
EGFR-TKIs and SOC therapy. Two main reasons may
explain the potency of RN486: i) RN486 is a reversible
allosteric BTK inhibitor that interact with K430 [42], a
residue critical for protein kinase activity [43], and does
not cross react with EGFR family member, being there-
fore specific for BTK only; ii) Ibrutinib is metabolized
and inactivated by the two isoforms of the CYP3 detoxi-
fying enzyme 3A4 and 3A5 [44], both of them overex-
pressed in NSCLC [45]. This information might be
relevant in the planning of clinical trials with BTK
inhibitors.
In summary, we indicate that p65BTK is a putative
theranostic marker in NSCLC in non-smoker patients
with EGFR-wt AdC. Furthermore, our in vitro data show
a synergistic effect of BTK inhibitors with targeted ther-
apy and SOC chemotherapy in NSCLC treatment. In
fact, the addition of BTK inhibitors to EGFR-targeted
therapy or chemotherapy is effective in re-sensitizing
NSCLC cells with an EGFR-wt and defects in the RAS/
MAPK pathway, thus scarcely responsive to current
Table 4 Synergism between BTK inhibitors and Chemoterapy
Ibrutinib AVL-292 RN486
CisPt Pemetr Gemcitab CisPt Pemetr Gemcitab CisPt Pemetr Gemcitab
Calu-6 0.11 ant ant 0.3 0.23 0.28 0.04 0.05 0.01
SK-Lu-1 0.09 ant ant 0.28 0.21 0.25 0.07 0.05 0.07
NCI-H1975 0.16 0.38 0.33 ant 0.51 0.52 0.08 0.05 0.02
NCI-H2228 0.22 0.41 0.41 0.47 0.43 0.47 0.06 0.06 0.03
Combination Index (CI) was calculated as reported by Fransson (Fransson, A., et al. (2016) J Ovarian Res 9 [1]: 27) and detailed in material and methods
0.8 < CI < 1.2 = additive effect, CI < 0.8 = synergistic effect (CI < 0.5 = strong synergistic effect), CI > 1.2 = sub-additive effect, ant = antagonistic effect
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treatments. Further studies are needed to better disclose
mechanism of action of BTK inhibitors and criteria to
accurately stratify NSCLC patients eligible for anti-BTK
therapy.
Conclusions
Our results indicate that p65BTK is a potential thera-
peutic target in advanced NSCLC. In the clinical setting,
p65BTK inhibition might be an effective strategy for
overcoming resistance of NSCLC to chemotherapy and
targeted therapy in lung adenocarcinoma patients.
Additional files
Additional file 1: Figure S1. BN30 antibody characterization. a Western
blot analysis of lysates from HCT116p53KO cells harvested 48hs after
transfection with control (Luc) or p65BTK-specific (BTK) siRNA and used to
produce cells blocks. b IHC using BN30 on slides from cells blocks; bar:
50 μM. 40X magnification. c Western blot analysis of lysates from SW480
cells harvested 48hs after transfection with control (Luciferase) or p65BTK-
specific (BTK) siRNA and from B-cell lymphoblastic leukemia cell line
Nalm-6, which expresses both p65 and p77BTK. BD#611117: anti-BTK anti-
body from Becton Dickinson raised against the N-term of the protein and
not cross-reacting with p65BTK (PDF 1492 kb)
Additional file 2: Table S1. Clinicopathological characteristics of NSCLC
patients (n = 383). LGT: Lepidic growth type; AdC: adenocarcinoma; LC,
large cell AdC; SCC: squamous cell carcinoma; AdC/SCC, mixed adeno-
squamous carcinoma; R, rearranged. pTx or pNx, this information could
not be established. (PDF 72 kb)
Additional file 3: Figure S2. p65BTK expression in NSCLC or AdC non-
smoker patients stratified by ALK translocation (T) (PDF 247 kb)
Additional file 4: Figure S3. p65BTK expression in T cells. FACS-purified
CD3 cell lysate was tested for p65BTK expression by BN49 antibody and
for p77BTK expression using the anti-BTK (#611117, from Becton Dickin-
son. 100 pg of purified p77BTK (#B4312, Sigma-Aldrich) were also loaded
as a positive control. (PDF 469 kb)
Additional file 5: Table S2. p65BTK mRNA but not p77BTK mRNA is
expressed in NSCLC cell lines. mRNA expression was evaluated by RT-PCR
using primers specific for each of the two isoforms [18]. (PDF 90 kb)
Additional file 6: Figure S4. p65BTK is overexpressed and active in
NSCLC cell lines scarcely responsive to EGFR inhibition. a
Immunofluorescence staining of phosphorylated p65BTK (pBTK) in
untreated human p53-null NSCLC cell lines. Nuclei were counterstained
with DAPI. b Western blot analysis of phosphorylated p65BTK in NSCLC
cell lines. 100 pg of purified activated form p77BTK (#B4312, Sigma-
Aldrich) were also loaded as a positive control. Expression levels of total
p65BTK were assessed by BN49. Vinculin was used as a loading control. c
Immunofluorescence staining of pBTK after 2 h treatment of SK-Lu-1 cells
with BTK inhibitors (IBRU20 = Ibrutinib 20 μM; AVL10 = AVL-292 10 μM;
RN10 = RN486 10 μM). d Western blot analysis of phosphorylated p65BTK
in SK-Lu-1 cells after 2 h treatment with BTK inhibitors (IBRU20 = Ibrutinib
20 μM; AVL10 = AVL-292 10 μM; RN10 = RN486 10 μM. Expression levels of
total p65BTK were assessed by BN49. Vinculin was used as a loading con-
trol. (PDF 3221 kb)
Additional file 7: Figure S5. Cell death triggered by the combination
of BTK inhibitors and target therapy or SOC chemotherapy is apoptosis. a
Caspase-3/7 activation after 24 hs treatment of SK-Lu-1 and NCI-H2228
cells with the indicated drugs, as assessed by luminometric assay. Error
bars represent mean ± SEM. n = 3. b Cell viability of SK-Lu-1 and NCI-
H2228 cell lines in response to combinations of BTK inhibitor RN486 and
EGFR inhibitor Gefitinib or Cisplatin. (T0 = time 0; NT = untreated; RN10 =
RN486 10 μM; QVD 10 = Q-VD-OPh 10 μM; GEF20 = Gefitinib 20 μM;
CIS10 = Cisplatin 10 μM). X-axis crosses in correspondence of T0 values
(before starting the treatment); 72 h values are then expressed as the per-
centage variation relative to the initial cell number. Data are presented as
mean ± SEM. n≥ 3 independent experiments. (PDF 301 kb)
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Fig. 7 p65BTK inhibition reverts resistance of NSCLC cell lines to
chemotherapy. Cell viability of human p53-null NSCLC cell lines in
response to different combinations of BTK and SOC chemotherapeutic
agents (T0 = time 0; NT = untreated; CIS10 = Cisplatin 10 μM; PEM10 =
Pemetrexed 10 μM; GEM10 = Gemcitabine 10 μM; IBRU20 = Ibrutinib
20 μM; AVL10 = AVL-292 10 μM; RN10 = RN486 10 μM). X-axis crosses in
correspondence of T0 values (before starting the treatment); 72 h
values are then expressed as the percentage variation relative to the
initial cell number. Scale on Y-axis is adapted to the different growth
rates shown by each cell line. Data are presented as mean ± SEM. n≥ 3
independent experiments. * indicates p < 0.05 vs T0 values
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